Multiple endocrine neoplasia type 1 other imaging findings

Revision as of 14:57, 10 September 2015 by Ammu Susheela (talk | contribs)
Jump to navigation Jump to search

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 other imaging findings

CDC on Multiple endocrine neoplasia type 1 other imaging findings

Multiple endocrine neoplasia type 1 other imaging findings in the news

Blogs on Multiple endocrine neoplasia type 1 other imaging findings

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Other imaging studies for multiple endocrine neoplasia type 1 include Fluoro-di-glucose-PET/CT, which demonstrates hepatic metastases and Venous sampling, angiography and endovascular procedures, such as trans-arterial chemo-embolization (TACE)

Nuclear Medicine[1]

  • Common radiopharmaceutical is 111-indium-pentetreotide, which is a ligand for somatostatin receptor on the cell membrane of many NETS. Multiple tumour sites and/or metastasis can be identified using a gamma-camera to detect the emitted radiation
  • Can be used in combination with cross-sectional imaging modalities to aid staging e.g. SPECT or PET-CT or PET-MRI 6
  • Can be used to predict response to nuclear medicine based therapies, and, in some cases, to assess response to treatment.
  • Care should be taken with interpretation of images as drugs can interfere with somatostain receptor expression, e.g. interferon.
  • NETS can differentiate into tumors that do not express somatostatin receptors can become ‘image negative’ making reoccurrence or metastases more challenging to detect other radiopharmaceuticals are also used, based on certain physiological characteristics e.g. cell surface receptors or uptake of molecules.
  • Gallium-68 labelled somatostatin analogues (PET/CT) – thought to be more sensitive in detecting NETS expect pulmonary and hepatic metastases for aggressive, rapidly growing tumors (i.e. high metabolism) Fluoro-di-glucose-PET/CT can be used (FDG-PET)
  • F18 DOPA and C11 Hydroxytryptophan may be used in future but are not routinely available

Invasive Imaging Techniques

  • Venous sampling can be used in small functional NETS where cross sec-tional imaging is equivocal.
  • Multiple endocrine neoplasia type 1 can present with multiple lesions. Functional NETS can be identified from these, using calcium stimulation with venous sampling.
  • Angiography and endovascular procedures, such as trans-arterial chemo-embolization (TACE), can be used to treat hepatic metastases.

Reference

  1. "Radiopedia2015 Gastrointestinal neuroendocrine tumours [Dr Dalia Ibrahim and Dr Jan Smith]".